BOSTON SCIENTIFIC RECEIVES CE MARK FOR LOTUS™ VALVE SYSTEM
Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control
Natick, Mass. (Oct. 28, 2013) – Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Lotus™ Valve System, the company’s advanced transcatheter aortic valve replacement (TAVR) technology. This key approval offers a unique and effective new treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement.
The Lotus Valve System is immediately available to select centers in Europe, with commercial site expansion accelerating as physicians and centers become fully trained.